Relapsing macrophage activating syndrome in a 15-year-old girl with Still's disease: a case report
Open Access
- 19 November 2009
- journal article
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 3 (1) , 138
Abstract
Macrophage activating syndrome is a severe, potentially life-threatening condition that may accompany Still's disease. It is characterized by fever, hepatosplenomegaly, lymphadenopathy, severe cytopenia, serious liver dysfunction, coagulopathy and neurologic involvement. The principal treatment for patients with this syndrome includes etoposide 150 mg/2 M twice a week for two weeks, dexamethasone 10 mg/2 M for two weeks and cyclosporine 3 mg/kg to 5 mg/kg for a longer period. Cases of relapse of macrophage activating syndrome are relatively rare.Keywords
This publication has 17 references indexed in Scilit:
- Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis.2006
- HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosisPediatric Blood & Cancer, 2006
- Diagnosis and management of adult onset Still's diseaseAnnals of the Rheumatic Diseases, 2006
- Macrophage Activation Syndrome in Children with Systemic-Onset Juvenile Chronic ArthritisActa Haematologica, 2005
- Macrophage activation syndrome: a potentially fatal complication of rheumatic disordersArchives of Disease in Childhood, 2001
- Percentage of glycosylated serum ferritin remains low throughout the course of adult onset Still's diseaseAnnals of the Rheumatic Diseases, 2000
- Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still's disease.1998
- The Role of Cytokines in the Regulation of Ferritin Expression1994
- Adult Stillʼs DiseaseMedicine, 1991
- Adult onset Still's disease and viral infections.Annals of the Rheumatic Diseases, 1988